Immunity in Experimental Salmonellosis I. Protection Induced by Rough Mutants of Salmonella typhimurium

Sugar-Phosphate Toxicities Attenuate Salmonella Fitness in the Gut

Pathogens are becoming resistant to antimicrobials at an increasing rate, and novel therapeutic strategies are needed. Using Salmonella as a model, we have investigated the induction of sugar-phosphate toxicity as a potential therapeutic modality. The approach entails providing a nutrient while blocking the catabolism of that nutrient, resulting in the accumulation of a toxic intermediate. We hypothesize that this build-up will decrease the fitness of the organism during infection given nutrient availability. We tested this hypothesis using mutants lacking one of seven genes whose mutation is expected to cause the accumulation of a toxic metabolic intermediate. The araD, galE, rhaD, glpD, mtlD, manA, and galT mutants were then provided the appropriate sugars, either in vitro or during gastrointestinal infection of mice. All but the glpD mutant had nutrient-dependent growth defects in vitro, suggestive of sugar-phosphate toxicity. During gastrointestinal infection of mice, five mutants had decreased fitness. Providing the appropriate nutrient in the animal's drinking water was required to cause fitness defects with the rhaD and manA mutants and to enhance the fitness defect of the araD mutant. The galE and mtlD mutants were severely attenuated regardless of the nutrient being provided in the drinking water. Homologs of galE are widespread among bacteria and in humans, rendering the specific targeting of bacterial pathogens difficult. However, the araD, mtlD, and rhaD genes are not present in humans, appear to be rare in most phyla of bacteria, and are common in several genera of Enterobacteriaceae, making the encoded enzymes potential narrow-spectrum therapeutic targets. IMPORTANCE Bacterial pathogens are becoming increasingly resistant to antibiotics. There is an urgent need to identify novel drug targets and therapeutic strategies. In this work we have assembled and characterized a collection of mutations in our model pathogen, Salmonella enterica, that block a variety of sugar utilization pathways in such a way as to cause the accumulation of a toxic sugar-phosphate. Mutations in three genes, rhaD, araD, and mtlD, dramatically decrease the fitness of Salmonella in a mouse model of gastroenteritis, suggesting that RhaD, AraD, and MtlD may be good narrow-spectrum drug targets. The induction of sugar-phosphate toxicities may be a therapeutic strategy that is broadly relevant to other bacterial and fungal pathogens.

Sugar-Phosphate Toxicities

Accumulation of phosphorylated intermediates during cellular metabolism can have wide-ranging toxic effects on many organisms, including humans and the pathogens that infect them. These toxicities can be induced by feeding an upstream metabolite (a sugar, for instance) while simultaneously blocking the appropriate metabolic pathway with either a mutation or an enzyme inhibitor. Here, we survey the toxicities that can arise in the metabolism of glucose, galactose, fructose, fructose-asparagine, glycerol, trehalose, maltose, mannose, mannitol, arabinose, and rhamnose. Select enzymes in these metabolic pathways may serve as novel therapeutic targets. Some are conserved broadly among prokaryotes and eukaryotes (e.g., glucose and galactose) and are therefore unlikely to be viable drug targets. However, others are found only in bacteria (e.g., fructose-asparagine, rhamnose, and arabinose), and one is found in fungi but not in humans (trehalose). We discuss what is known about the mechanisms of toxicity and how resistance is achieved in order to identify the prospects and challenges associated with targeted exploitation of these pervasive metabolic vulnerabilities.

The extradomain a of fibronectin enhances the efficacy of lipopolysaccharide defective Salmonella bacterins as vaccines in mice

The Extradomain A from fibronectin (EDA) has an immunomodulatory role as fusion protein with viral and tumor antigens, but its effect when administered with bacteria has not been assessed. Here, we investigated the adjuvant effect of EDA in mice immunizations against Salmonella enterica subspecies enterica serovar Enteritidis (Salmonella Enteritidis). Since lipopolysaccharide (LPS) is a major virulence factor and the LPS O-polysaccharide (O-PS) is the immunodominant antigen in serological diagnostic tests, Salmonella mutants lacking O-PS (rough mutants) represent an interesting approach for developing new vaccines and diagnostic tests to differentiate infected and vaccinated animals (DIVA tests). Here, antigenic preparations (hot-saline extracts and formalin-inactivated bacterins) from two Salmonella Enteritidis rough mutants, carrying either intact (SEΔwaaL) or deep-defective (SEΔgal) LPS-Core, were used in combination with EDA. Biotinylated bacterins, in particular SEΔwaaL bacterin, decorated with EDAvidin (EDA and streptavidin fusion protein) improved the protection conferred by hot-saline or bacterins alone and prevented significantly the virulent infection at least to the levels of live attenuated rough mutants. These findings demonstrate the adjuvant effect of EDAvidin when administered with biotinylated bacterins from Salmonella Enteritidis lacking O-PS and the usefulness of BEDA-SEΔwaaL as non-live vaccine in the mouse model.

Animal models of Salmonella infections: enteritis versus typhoid fever

The most common disease syndromes caused by Salmonella serotypes in humans, typhoid fever and enteritis, can be modeled using Salmonella enterica serotype Typhimurium infections in mice and calves, respectively. This article reviews murine typhoid and bovine enteritis and discusses strengths, limitations and distinctive features of these animal models.

Pathogenicity and protective effect of rough mutants of Salmonella species in germ-free piglets

In this study, two stable, rough, streptomycin-sensitive Salmonella mutants with different types of genetic defects were used to colonize groups of germ-free (GF) piglets. The lipopolysaccharide (LPS) of Salmonella typhimurium SF 1591 was of the Ra chemotype (complete core), whereas the LPS of the S. minnesota mR 595 deep-rough mutant contained only lipid A and 2-keto-3-deoxyoctulosonic acid (Re chemotype). Both strains readily colonized the intestinal tracts of GF piglets and were stable during the whole experiment. All animals survived, and only transient fever was observed in some piglets colonized with the SF 1591 strain. Finally, streptomycin and virulent, smooth, streptomycin-resistant S. typhimurium LT2 were administered perorally 1 week later. All piglets colonized previously with the deep-rough mutant mR 595 died of sepsis, in contrast to piglets infected with the LT2 strain and colonized with the SF 1591 mutant, all of which survived. This difference is explained by the penetration of the mesenteric lymph nodes, spleen, and liver by great numbers of live bacteria in the latter case, resulting in prominent systemic and local immune responses. On the other hand, live bacteria were found only rarely in the mesenteric lymph nodes of animals colonized with the mR 595 strain and a negligible antibody response was observed.

Systemic and local antibody response in mice induced by a recombinant peptide fragment from Giardia lamblia variant surface protein (VSP) H7 produced by a Salmonella typhimurium vaccine strain

Previous experimental infections of mice with the intestinal protozoan Giardia lamblia had revealed that antigenic variation of the parasite was associated with the major surface antigen, named variant surface protein (VSP). In the present study, a gene segment of the VSP (VSPH7) from the well-characterized G. lamblia clone GS/M-83-H7 was expressed in the live-attenuated Salmonella typhimurium vaccine strain LT2M1C. The recombinant vaccine was assessed for its potential to induce both a systemic and a local antibody response in mice. Peroral administration of the vaccine stimulated synthesis of serum IgG and intestinal IgA antibodies directed against Salmonella antigens as well as against VSPH7. With respect to the anti-VSPH7 antibody concentrations, vaccination of animals resulted in systemic and local antibody responses similar to those induced by experimental or natural infections of mice with G. lamblia clone GS/M-83-H7. Subclass specification of serum anti-VSPH7 IgG demonstrated THelper 2-cell dependent IgG1- and/or IgG2b-type antibody production. No significant THelper 1-cell dependent IgG2a-type anti-VSPH7 antibody production was detected in infected or in vaccinated animals. Taken together, these data indicate a strong intrinsic antigenicity of VSPH7, which stimulates a THelper 2-cell pathway of the murine immune system, independent of the route of antigen administration. Furthermore, the high immunostimulatory potential of the recombinant Salmonella/VSPH7 model vaccine suggests application of LT2M1C as an enteric biocarrier for the identification of putative new target vaccines in giardiasis.

Polysaccharide synthesis in relation to nodulation behavior of Rhizobium leguminosarum

In this study, we characterized four Tn5 mutants derived from Rhizobium leguminosarum RBL5515 with respect to synthesis and secretion of cellulose fibrils, extracellular polysaccharides (EPS), capsular polysaccharides, and cyclic beta-(1,2)-glucans. One mutant, strain RBL5515 exo-344::Tn5, synthesizes residual amounts of EPS, the repeating unit of which lacks the terminal galactose molecule and the substituents attached to it. On basis of the polysaccharide production pattern of strain RBL5515 exo-344::Tn5, the structural features of the polysaccharides synthesized, and the results of an analysis of the enzyme activities involved, we hypothesize that this strain is affected in a galactose transferase involved in the synthesis of EPS only. All four mutants failed to nodulate plants belonging to the pea cross-inoculation group; on Vicia sativa they induced root hair deformation and rare abortive infection threads. All of the mutants appeared to be pleiotropic, since in addition to defects in the synthesis of EPS, lipopolysaccharide, and/or capsular polysaccharides significant increases in the synthesis and secretion of cyclic beta-(1,2)-glucans were observed. We concluded that it is impossible to correlate a defect in the synthesis of a particular polysaccharide with nodulation characteristics.

Salmonella choleraesuis strains deficient in O antigen remain fully virulent for mice by parenteral inoculation but are avirulent by oral administration

O-antigen-deficient derivatives of two mouse-virulent strains of Salmonella choleraesuis (serogroup C1; O-6,7) were constructed by transduction of a long deletion of the rfb operon. Strains SN36 and SN57 were derived from the smooth ancestor SL2824, while SN37 was derived from the smooth ancestor SL2840. These rfb deletion derivatives (rfb strains) had typical bacteriophage sensitivity patterns of "rough" Salmonella strains and were at least 200,000 times more sensitive to serum than their smooth ancestors. Lipopolysaccharides (LPS) extracted from them consisted only of two low-molecular-weight bands and lacked the ladderlike pattern of bands seen in the LPS of their smooth ancestors. The LPS from the rfb strains did not react in an enzyme immunoassay with any of three monoclonal antibodies directed against different epitopes of the O-6,7 antigen but reacted well with at least one of three monoclonal antibodies specific for core epitopes. The data were consistent with inability of these strains to synthesize O-specific chains and showed that the LPS extracted from SN57 was of chemotype Ra and that from SN36 was of chemotype Rb1, while that of SN37 consisted of a mixture of the two chemotypes. The virulence of these strains was tested by various routes in BALB/c mice. All three O-antigen-deficient derivatives were about as virulent as their "smooth" ancestors by the intraperitoneal and intravenous routes (50% lethal dose, 20 to 700 bacteria) but, unlike their ancestors, were avirulent by the oral route (50% lethal dose, greater than or equal to 5 x 10(9) bacteria). This suggests that the major role of smooth LPS in the mouse virulence of S. choleraesuis is to facilitate survival in the gastrointestinal tract and eventual entry into deeper tissues.

Humoral and cellular immune response in mice and dogs induced by a recombinant Echinococcus multilocularis antigen produced by a Salmonella typhimurium vaccine strain

A gene fragment (II/3-10) from the cestode Echinococcus multilocularis coding for a species-specific antigen was expressed in the live attenuated Salmonella typhimurium vaccine strain LT2 M1C. The recombinant vaccine (S. typhimurium + pVM II/3-10) was assessed for its potential to induce both a humoral and cell-mediated immune response in mice and dogs. Both subcutaneous and peroral administration of the vaccine resulted in antibody synthesis and lymphocyte priming of C57BL/6J mice against S. typhimurium antigens as well as against the recombinant E. multilocularis antigen. Two vaccinated (subcutaneous and peroral) dogs showed a strong humoral immune response to S. typhimurium antigens and to the recombinant E. multilocularis antigen, but proliferation of peripheral blood lymphocytes was not detectable against the bacterial S. typhimurium antigens. Regarding the recombinant E. multilocularis antigen, borderline lymphocyte proliferation was demonstrated following subcutaneous and none following peroral administration of the recombinant vaccine to dogs.

Vaccination route, infectivity and thioglycollate broth administration: effects on live vaccine efficacy of auxotrophic derivatives of Salmonella choleraesuis

An aromatic-dependent, therefore non-virulent, derivative of a mouse-virulent strain of Salmonella choleraesuis previously shown not to be effective as a live vaccine when given intraperitoneally (i.p.) to Itys mice, was administered to BALB/c mice. Two doses given i.p. or by feeding did not protect against i.p. or oral challenge with 50 to 5000 LD50 of the virulent ancestor strain. By contrast two doses given intravenously (i.v.) gave almost complete protection against i.p. or oral challenge with 500 LD50 and some protection against larger doses. The number of live bacteria (cfu) in the liver and spleen 24 h after administration of the live vaccine was less than 1% of the number inoculated i.p., but c. 25% of the number injected i.v. The number of cfu in the gut 24 h after oral vaccine administration was only c 10(-5) of the number fed. Administration of thioglycollate broth i.p. 5 days before i.p. vaccination increased recovery of live vaccine cfu in the liver and spleen and its protective efficacy. In each case the live vaccine did not multiply extensively in vivo. We have previously shown that a purine- and a thymine-requiring derivative of S. choleraesuis were each considerably attenuated but unlike the aro derivative were effective as i.p. live vaccines in mice. Doses of these strains (c. 10(4) cfu) found protective were administered i.p. to BALB/c mice. Each strain multiplied extensively in the liver and spleen to c. 10(7) cfu by day 6. All these results are in agreement with a correlation of protective efficacy of a live vaccine with the persistence of a large number of the vaccine bacteria in the liver and spleen for several days.

Salmonella typhimurium virulence in a burned-mouse model

Various features of salmonellosis were examined in a burned-mouse model. In this model, which uses an outbred mouse strain, a challenge dose of ca. 100 CFU with any of several strains of Salmonella typhimurium caused a fatal infection. A variety of mutated strains attenuated for virulence in Salmonella-susceptible parenterally infected mice were also attenuated in the burned-mouse model. When administered as live vaccines injected intraperitoneally the same attenuated strains provided between slight and complete protection against subsequent lethal challenge subcutaneously at the site of a burn. The correspondence of results obtained in the burned-mouse model with those seen in other mouse models coupled with the unique advantages of the burned-mouse model argue for the usefulness of the model in studies of salmonellosis and in testing of strains constructed for use as live vaccines.

A galE via (Vi antigen-negative) mutant of Salmonella typhi Ty2 retains virulence in humans

We have recently described the construction of a galE derivative of Salmonella typhi Ty2 (Ty2H1) which had a 0.4-kilobase deletion in the galE gene and was sensitive to galactose-induced lysis when cultured with greater than or equal to 0.06 mM galactose (D. M. Hone, R. Morona, S. Attridge, and J. Hackett, J. Infect. Dis. 156:167-174, 1987). We now report the selection of a rifampin-resistant, via derivative of Ty2H1, EX462. Compared with the Ty2 parent strain, EX462 was serum sensitive and highly attenuated in the mouse mucin virulence assay. When four human volunteers ingested 7 X 10(8) viable EX462, two became ill and developed a typhoidlike disease with fever and bacteremia. Blood isolates from these individuals were indistinguishable from the vaccine strain by a variety of criteria. We concluded that, even in a via background, the galE mutation was not attenuating for S. typhi in humans.

Temperature-sensitive growth mutants as live vaccines against experimental murine salmonellosis

Temperature-sensitive growth mutants of Salmonella enteritidis, NUB 209 and NUB 323, characterized as protein synthesis mutants, were unable to proliferate at 37 C and lost the parent's virulence. In mice, these mutants conferred high levels of protection as live vaccines. Although the vaccination effect of NUB 323 was not so good as that of NUB 209, NUB 323 was preferred as a safer live vaccine because this mutant was completely avirulent and no back mutation appeared.

The effects of O-antigen character and enterobacterial common antigen content on the in vivo persistence of aromatic-dependent Salmonella sp. live-vaccine strains

Aromatic-dependent (aro) derivatives of Salmonella choleraesuis like aro S. typhimurium are non-virulent but, unlike them, are ineffective as live vaccines in mice, given i.p. An aro derivative of S. choleraesuis did not persist in the liver and spleen (RES) of mice after i.p. inoculation whereas a similar derivative of S. typhimurium persisted. S. choleraesuis (O group C1; O-6,7) and S. typhimurium [O group B; O-(1),4(5),12] differ in O antigen of LPS, determined by chromosomal locus, rfb. Three pairs of nearly-isogenic aro derivatives, one member O-6,7 and the other O-(1),4,(5),12, were constructed in two lines of S. typhimurium by replacement of their B-rfb genes with the C1-rfb genes of S. choleraesuis. In tests for persistence after mixed or separate i.p. inoculation of equal doses into BALB/c mice the O-(1),4,(5),12 member of each pair was recovered as CFU in the RES at ca. 100-fold greater number than the O-6,7 member at 24 hours post-inoculation and subsequently. O-6,7 derivatives of S. typhimurium constructed as described above by a simple replacement of group B with group C-rfb locus synthesise only trace (tr) amounts of enterobacterial common antigen (ECA). An ECA+ (able to make normal levels of ECA) derivative of one aro, O-6,7 S. typhimurium strain was constructed by replacement of its B-rfe locus with the C-rfe locus of S. choleraesuis. Tested by mixed inoculation i.p. this strain persisted in the RES in numbers 10-fold greater than its O-6,7 ECAtr but 5-10-fold lesser than its O-(1),4,(5),12 cousins. Thus both O-specificity and ECA contribute to the survival of salmonella species in mice as determined by in vivo persistence of non-multiplying aro derivatives.

Test of the virulence and live-vaccine efficacy of auxotrophic and galE derivatives of Salmonella choleraesuis

Aromatic compound-dependent (aro) derivatives of three mouse-virulent strains of Salmonella choleraesuis (Salmonella cholerae-suis) were constructed and shown to be nonvirulent for mice (intraperitoneal [i.p.] 50% lethal dose [LD50], greater than 5 X 10(6) CFU). A pur derivative, and a thy derivative, each of a different virulent parent, remained moderately virulent (i.p. LD50S for BALB/c mice, ca. 10(5) and 5 X 10(4) CFU, respectively). Tested as live vaccines i.p., the aro strains were ineffective in salmonella-susceptible BALB/c and C57BL/6 mice but were somewhat effective in salmonella-resistant CBA/J mice and in outbred CD-1 mice. The pur and thy strains were effective as live vaccines in BALB/c mice when given in sublethal doses. Two previously isolated nonvirulent galE derivatives of S. choleraesuis (i.p. LD50 in BALB/c mice, greater than 10(6) CFU) were also ineffective as live vaccines in BALB/c and C57BL/6 mice. The main antigenic difference between S. choleraesuis (O-6,7) and S. typhimurium (O-4,12) is in O-antigen character, thought to largely determine the specificity of protection in salmonellosis. Paired, nearly isogenic O-6,7 and O-4,12 derivatives were constructed from an aro S. typhimurium strain of proven efficacy as a live vaccine. Used as live vaccines, the O-4,12 member protected BALB/c mice against challenge with virulent S. typhimurium, whereas the O-6,7 member did not protect against virulent S. choleraesuis. However, BALB/c mice vaccinated with the O-6,7 member and mice vaccinated with an aro S. choleraesuis strain were protected against challenge with a moderately virulent (LD50, 5 X 10(4) CFU) O-6,7 derivative of an S. typhimurium strain.

Safety, infectivity, immunogenicity, and in vivo stability of two attenuated auxotrophic mutant strains of Salmonella typhi, 541Ty and 543Ty, as live oral vaccines in humans

Two Salmonella typhi mutants, 541Ty (Vi+) and 543Ty (Vi-), auxotrophic for p-aminobenzoate and adenine, were evaluated as live oral vaccines. 33 volunteers ingested single doses of 10(8), 10(9), or 10(10) vaccine organisms, while four others received two 2 X 10(9) organism doses 4 d apart. No adverse reactions were observed. Vaccine was recovered from coprocultures of 29 of 37 vaccinees (78%) and from duodenal string cultures of two; repeated blood cultures were negative. The humoral antibody response to S. typhi O, H, Vi, and lysate antigens in serum and intestinal fluid was meager. In contrast, all vaccinees manifested cell-mediated immune responses. After vaccination, 69% of vaccinees overall and 89% of recipients of doses greater than or equal to 10(9) responded to S. typhi particulate or purified O polysaccharide antigens in lymphocyte replication studies but not to antigens of other Salmonella or Escherichia coli. All individuals, postvaccination, demonstrated a significant plasma-dependent mononuclear cell inhibition of wild S. typhi.

Clonal analysis of primary B cells responsive to the pathogenic bacterium Salmonella typhimurium

In the present study, a modification of the splenic focus system is used to analyze the S. typhimurium strain TML (TML)-specific B cell repertoire. The results show that the frequency of primary TML-specific splenic B cells in CBA/Ca mice is approximately 1 per 10(5) B cells and less than 30% of these B cells are specific for LPS. In contrast, the frequency of memory TML-specific cells is approximately 1 per 5-8 X 10(3) splenic B cells and greater than 95% of these B cells are specific for LPS. These results suggest that the frequency of primary TML-specific B cells is extremely low and that it expands 15-20-fold after antigen exposure. It is interesting that less than 30% of the primary B cells are specific for the LPS molecule since it is considered to be the major antigenic determinant on Salmonella organisms. Furthermore, the majority of the LPS-specific anti-TML antibody-producing clones are directed against the LPS O antigen region. Conversely, more than half to two-thirds of the memory LPS-specific anti-TML B cell clones are directed against the KDO or lipid A region of the LPS molecule. These results indicate that the preferential expansion of LPS-specific B cell clones observed after immunization resides primarily in the B cell subsets responsive to the KDO/lipid A moieties on the LPS molecule. Finally, unlike B cell responses to chemically defined antigens, TML stimulates very little IgG1 antibody. IgG2 and IgA isotypes appear to play a predominant role in anti-TML antibody responses, although all H chain classes are produced to some extent. Collectively, these findings are consistent with the responses reported for two other natural antigens, HA and PC. Hence, the pattern of stimulation by infectious agents, such as S. typhimurium, appears to be distinct from that of synthetic antigens. Thus, the studies presented herein have begun to provide insights into those subsets of B cells responsive to S. typhimurium and other infectious disease organisms.

Some galE mutants of Salmonella choleraesuis retain virulence

galE mutants were isolated from three mouse-virulent strains of Salmonella choleraesuis (of group C1, O antigen 6,7) by selection for resistance to 2-deoxygalactose. The galE derivative of strain 381 comprised two components: galactose sensitive, thought to be the original mutant; and galactose resistant, presumably by a second mutation reducing galK or galT function or both. The galactose-sensitive component had an intraperitoneal 50% lethal dose for BALB/c mice of ca. 4 X 10(6) CFU, whereas the galactose-resistant component was about as virulent as its gal+ parent, with a 50% lethal dose of ca. 100 CFU. The galE mutant of strain 110 was somewhat sensitive to galactose, as shown by retardation of growth; its 50% lethal dose, ca. 500 CFU, was not much greater than the ca. 200 CFU value for its parent. The galE mutant of strain 117 showed the same partial sensitivity to galactose as strain 110 galE, but was nonvirulent (50% lethal dose of ca. 10(6) CFU versus ca. 400 CFU for its parent). Growth on galactose-supplemented medium restored the smooth phenotype, as indicated by phage sensitivity to three of the four galE strains, but only partially so for the strain 117 galE mutant. The retention of parental virulence by galE mutants of S. choleraesuis which are galactose resistant or somewhat galactose sensitive contrasts with the greatly reduced virulence of galactose-resistant galE mutants of Salmonella typhimurium and Salmonella typhi; this difference may result from the absence of galactose from the O repeat unit in the lipopolysaccharide of group C1 salmonellae.

Galactose epimeraseless mutants of Salmonella typhimurium as live vaccines for calves

The purpose of the study was to evaluate the safety and efficacy of a galactose epimeraseless mutant of Salmonella typhimurium administered as an oral vaccine to one week old calves and to investigate properties of galactose epimeraseless mutants which affect their virulence and immunogenicity. The galactose epimeraseless mutant S. typhimurium strain G30D caused diarrhea and fever in three calves to which it was administered orally at a dose of 10(10) organisms; all three calves died following challenge with virulent S. typhimurium ten days postvaccination. Mild illness developed in four calves vaccinated with a dose of 9 X 10(6) organisms and one of these calves survived challenge. Three unvaccinated calves died following challenge. The vaccine organism persisted in tissues and was shed for a prolonged period by calves which received 10(10) organisms. Studies of characteristics of galactose epimeraseless mutants of S. typhimurium showed that, in the presence of galactose, there is selection for secondary mutants which are galactose resistant. The studies indicate that galactose epimeraseless mutants of S. typhimurium are not good candidate live vaccine organisms for use in calves.

Molecular analysis of the virulence determinants of enterotoxigenic Escherichia coli isolated from domestic animals: applications for vaccine development

Enterotoxigenic strains of Escherichia coli are an important cause of diarrhoeal disease in young farm animals. Several virulence determinants have been shown to play a major role in the pathogenicity of these strains. The molecular structure of some of these determinants including adhesion fimbriae, heat-labile toxins and heat-stable toxins have been elucidated. This knowledge has made possible the development of novel vaccines effective against enterotoxigenic strains. In this short review, the structure of these virulence factors will be described and the implications for the development of future vaccines will be discussed.

The impact of new technologies on vaccine development

The ability to move genetic determinants between species using in vitro gene-manipulation techniques has opened up new approaches to vaccine development. This has rapidly grown into an exciting area of research in both academic and industrial laboratories. There are numerous scientific challenges which require multidisciplinary teams to solve problems in creating new immunogens. This has challenged our existing knowledge about protein structure and conformation, microbial pathogenicity and the immune system. Recombinant-DNA techniques are invaluable as tools of analysis and antigen production. The surface of micro-organisms can also be minutely explored with the use of synthetic peptides and monoclonal antibodies. Nevertheless, these new technologies do not allow us to circumvent the need for detailed understanding of pathogens and the disease process. What is apparent from the work carried out so far is that there are few easy answers to vaccine development and it is not realistic to expect rapid solutions to these problems. As there are many potential targets for constructing novel vaccines for both human and animal diseases, it is helpful to establish some priorities. There is a tendency to look at the existing effective vaccines and simply direct research at producing them more economically or with enhanced safety and stability. The advantage of this approach is that considerable background work will have already been carried out establishing the basis for the application of recombinant DNA techniques. However, this can also lead to conflicts (often within the same institute or company) between the new and old technologies. This could be to the detriment of the new technologies which are still only partly developed and may not be good enough yet to compete with existing vaccines in cost or efficacy. The more ambitious, and eventually more rewarding, approach is to attempt to develop new vaccines where none had existed before. There is a vast untapped market, especially in the parasitic diseases, but the scientific problems may be considerable and much more background work is likely to be necessary. Indeed, most of the work in this area is more accurately referred to as basic research rather than vaccine development as totally new, effective vaccines are still some way off. Having directed research towards a specific organism or disease there are still many options available as to the scientific strategy to adopt. As discussed in this review it may be possible to consider subunits, synthetic antigens and live (attenuated or heterologous) organisms as possible vaccines.(ABSTRACT TRUNCATED AT 400 WORDS)

New knowledge on pathogenesis of bacterial enteric infections as applied to vaccine development

Images

Salmonellosis in mice: studies on oral immunization with live avirulent vaccines

The avirulent Salmonella typhimurium galE strain G30, following oral feeding to mice, developed a state of immunity to a secondary oral challenge with virulent Salmonella typhimurium. This immunity was concommitant with the development of intestinal and serum antibodies and delayed-type hyepersensitivity (DTH) to Salmonella antigens. In contrast, repeated oral doses of a hybrid E. coli vaccine, which expresses the O antigens of Salmonella typhimurium, provided a lesser degree of immunity and, although able to stimulate the formation of serum antibodies, it elicited only a low level of intestinal antibodies and no measurable DTH.

The immunization of mice and calves with gal E mutants of Salmonella typhimurium

A galactose epimeraseless (gal E) mutant of Salmonella typhimurium was investigated in mice and calves for its suitability as a live vaccine. In mice, a very highly significant difference in the mortality rates was observed when vaccinated and non-vaccinated animals were challenged with virulent strains of S. typhimurium and S. dublin. In calves, doses of 10(6) and above of gal E mutant injected subcutaneously provided highly significant protection both in terms of mortality and prevalence of symptoms when calves were challenged orally with S. typhimurium. However, there appeared to be a relation between the vaccine and the presence of renal lesions and before gal E mutants can be recommended, further work is necessary to determine the pathogenesis of these lesions.

Characterization of the virulence and antigenic structure of Salmonella typhimurium strains with lipopolysaccharide core defects

The virulence and antigenic characters of Salmonella typhimurium strains, identical except for known lipopolysaccharide core defects, were compared. Smooth strains multiplied extensively and killed most mice. Deep rough strains containing only heptose I or heptose I and II in the rough core were completely eliminated after 6 h, whereas more superficial rough strains containing additional core sugars could be detected in low numbers (10(4) colony-forming units/g of tissue) for at least 7 days postinjection. Normal human serum exhaustively absorbed with certain rough strains was tested for ability to kill other rough strains. Two strains with the most superficial defects (rfaJ, rfaL) each had a unique serological character; strains with deeper defects showed much cross-reactivity. Similarities between the susceptibility of strains to the bactericidal effect of specifically absorbed serum correlated, in some cases, with similarities in in vivo behavior.

Immunogenicity of living and heat-killed Salmonella pullorum vaccines

Specific pathogen-free CD-1 and C57Bl mice were infected in a hind footpad with 5 x 10(4) viable Salmonella enteritidis cells or 10(7) viable S. pullorum cells. The resulting bacterial growth within the footpad, the draining lymph nodes, and the liver and spleen was followed for 14 days. Mice vaccinated with live S. enteritidis rapidly developed an effective antibacterial resistance to both intravenous and intragastric challenge with S. enteritidis SM(R). The viable inoculum of S. pullorum was rapidly eliminated from the normal mouse tissues and failed to induce a detectable anti-Salmonella resistance to parenteral or oral challenge with S. enteritidis. Heat-killed saline suspensions (200 mug, dry wt) of S. enteritidis or S. pullorum were unable to induce an effective antimicrobial resistance against a subsequent virulent Salmonella challenge. However, when the organisms were suspended in Freund complete adjuvant, both vaccines induced an antibacterial resistance to intravenous and intragastric challenge. Reduction of the antigenic dose from 200 to 40 mug did not greatly affect the protective value of the two killed vaccines against an intravenous challenge, but the level of protection observed with two 40-mug doses of S. pullorum was considerably reduced when the animals were infected intragastrically, suggesting that some quantitative differences existed between the sensitizing antigenic contents of the two test organisms.

Immunity in experimental salmonellosis. 3. Comparative immunization with viable and heat-inactivated cells of Salmonella typhimurium

Vaccination with viable cells of an avirulent Salmonella typhimurium galE mutant provides mice with solid specific immunity against subsequent infection with a virulent smooth strain. Such a live vaccine is markedly more potent than one prepared from inactivated cells of the virulent smooth strain. The superiority of the live vaccine is particularly well demonstrated when the oral route of application is used. The protective capacity of the galE mutant is based on its ability to synthesize complete smooth-like cell wall lipopolysaccharide in vivo.

Immunity in experimental salmonellosis. II. Basis for the avirulence and protective capacity of gal E mutants of Salmonella typhimurium

Salmonella typhimurium strains which are deficient in uridine diphosphate (UDP)-galactose-4-epimerase (gal E mutants) owe their outstanding protective capacity when used as live vaccine to the fact that when galactose is supplied exogenously, such as occurs in vivo, smooth cell wall lipopolysaccharides are synthesized. The mutants lose most of their protective capacity when this phenotypic curing is prevented by a second mutation of the kind found in strains LT(2)M(1)A (deficient in galactokinase) or E(32) (deficient in UDP-galactose-lipopolysaccharide transferase). Despite such phenotypic reversion, the gal E mutants are rendered avirulent as a result of galactose-induced bacteriolysis. Secondary mutants have been isolated which differ from each other with respect to the extent of galactose-induced lysis. The differences in galactose sensitivity are attributable to different activities of the other Leoloir pathway enzymes, namely, galactokinase and galactose-1-phosphate-uridyl transferase. The influence of these enzymes on lipopolysaccharide composition and galactose sensitivity and thus on virulence and immunogenicity of gal E mutants has been studied.